Page 2 - Processa Pharmaceuticals News Today

The Dow Jones index closed higher by more than 350 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

The Dow Jones index closed higher by more than 350 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or con...

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Free Report) CEO George K. Ng purchased 10,000 shares of Processa Pharmaceuticals stock in a transaction that occurred on Tuesday, January 30th. The stock was acquired at an average price of $2.70 per share, with a total value of $27,000.00. Following the transaction, the chief executive officer now owns […]

HANOVER, Md., Jan. 26, 2024 -- Processa Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy...

Processa Pharmaceuticals stock surge - 148.8% gain to $5.10 post Next Generation Capecitabine (NGC-Cap) Phase 1b success.

By Ben Glickman Shares of Processa Pharmaceuticals slumped Friday after the company's public offering priced. The stock was down 24% at $3.87 in morning...

By Ben Glickman Shares of Processa Pharmaceuticals surged Thursday morning after the company announced the completion of a safety evaluation of its potential...

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.33% to 37,932.33 while the NASDAQ rose 0.37% to 15,538.69. The S&P 500 also rose, gaining, 0.40% to 4,887.88.

Processa Pharmaceuticals shares are soaring Thursday after the company announced the completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine. Processa said the data obtained from the Phase 1b trial has been used to select two dosage regimens for the Phase 2 trial which will be in advanced or metastatic breast cancer given the FDA's agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.

U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The S&P 500 also rose, gaining, 0.26% to 4,881.28.